[13C]‐galactose breath test in a patient with galactokinase deficiency and spastic diparesis
Can Ficicioglu,
Didem Demirbas,
Britt Derks,
G. Shashidhar Pai,
David J. Timson,
Maria Estela Rubio‐Gozalbo,
Gerard T. Berry
Affiliations
Can Ficicioglu
Department of Pediatrics, Section of Biochemical Genetics The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine Philadelphia Pennsylvania USA
Didem Demirbas
Division of Genetics and Genomics, The Manton Center for Orphan Disease Research Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA
Britt Derks
Department of Pediatrics Maastricht University Medical Centre Maastricht The Netherlands
G. Shashidhar Pai
Medical University of South Carolina Children's Health, Division of Genetics Charleston South Carolina USA
David J. Timson
School of Pharmacy and Biomolecular Sciences University of Brighton Brighton UK
Maria Estela Rubio‐Gozalbo
Department of Pediatrics Maastricht University Medical Centre Maastricht The Netherlands
Gerard T. Berry
Division of Genetics and Genomics, The Manton Center for Orphan Disease Research Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA
Abstract Galactokinase deficiency is an inborn error of carbohydrate metabolism due to a block in the formation of galactose‐1‐phosphate from galactose. Although the association of galactokinase deficiency with formation of cataracts is well established, the extent of the clinical phenotype is still under investigation. We describe a 6‐year‐old female who was diagnosed with galactokinase deficiency due to cataract formation when she was 10 months of age and initially started on galactose‐restricted diet at that time for 5 months. She developed gait abnormality at 4 years of age. Breath tests via measurement of 13C isotope in exhaled carbon dioxide following 13C‐labeled galactose administration at carbon‐1 and carbon‐2 positions revealed oxidation rates within the normal range. The results in this patient strikingly contrast with the results of another patient with GALK1 deficiency that underwent breath testing with [1‐14C]‐galactose and [2‐14C]‐galactose. Extension of in vivo breath tests to other galactokinase patients is needed to better understand the pathophysiology of this disease.